Skip to main content

QNTM · Quantum Biopharma Ltd. · Documents

Track QNTM — free
$1.42 -0.10 (-6.58%) At close · Nov 19
Market Cap
$9.13M
Shares
6.43M
Volume · Nov 19 78.98K Avg daily vol (3M) 149.43K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 20-F filed Mar 26, 2026
2026
Nov 13
Current report 6-K
Shareholder equity rises 91% as Lucid-MS trial advances

Quantum BioPharma Ltd. reported 91% shareholder equity growth to US$9.77 million and US$12.22 million in combined cash and digital assets as of September 30, 2026. It also signed a study start-up agreement with Thermo Fisher Scientific for its Lucid-MS Phase 2 trial.

2 source passages
As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (excluding US$1.60 million of digital assets that were restricted at that date). Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025. Subsequent to quarter-end, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS in progressive multiple sclerosis, following the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA) in August 2026. Open the document at this passage
Nov 12
Current report 6-K
Nine-month net loss narrows to 17,320,779

Quantum Biopharma Ltd. reported a nine-month net loss of 17,320,779, down from 23,253,808, while period-end cash reached 3,556,345 and digital assets totaled 8,658,775.

Read from the first part of this long document
5 source passages
Quantum Biopharma Ltd. Nine months ended September 30, | | 2026 | 2025 Net loss | | (17,320,779) | (23,253,808) Cash and cash equivalents, end of the period | | 3,556,345 | 445,944 Digital assets | 6,10 | 8,658,775 | 2,213,575 Open the document at this passage
Nov 12
Current report 6-K
Closing raises C$80.86, voting power reaches approximately 68.22%

Quantum BioPharma raised C$80.86 by privately placing 26 Class A Multiple Voting Shares on November 9, 2026, lifting voting power to approximately 68.22%. Shareholders authorized consolidation of up to ten (10) pre-consolidation shares for one (1) post-consolidation share.

3 source passages
On November 9, 2026, the Company closed the Offering, issuing 26 Class A Multiple Voting Shares at a price of C$3.11 per Class A Multiple Voting Share for aggregate gross proceeds of C$80.86. Following the Offering, the 68 outstanding Class A Multiple Voting Shares represent approximately 68.22% of those votes. approved a special resolution authorizing the Board, in its sole discretion, to consolidate the Company’s issued and outstanding Class A Multiple Voting Shares and Class B Subordinate Voting Shares at a ratio of up to ten (10) pre-consolidation shares for one (1) post-consolidation share, as determined by the Board Open the document at this passage
Nov 5
Current report 6-K
70% MVS voting cap applies if cancellations exceed threshold

Quantum BioPharma Ltd. corrected fractional-share rounding for its proposed consolidation and clarified that the 70% cap on MVS holders’ voting power applies only if Class B Subordinate Voting Share cancellations would raise their aggregate voting power above 70%.

3 source passages
Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that it has filed a supplement (the “Supplement”) to its management information circular dated September 28, 2026 (the “Circular”) in connection with the annual general and special meeting of shareholders of the Company scheduled for November 10, 2026 at 1:00 p.m. (Eastern time) (the “Meeting”). The correction clarifies the treatment of fractional shares resulting from the consolidation. The Company also wishes to clarify that, in the event any Class B Subordinate Voting Shares are purchased for cancellation or otherwise cancelled such that the holders of MVS would thereby hold more than 70% of the aggregate voting power of the Company, the Company will implement a measure to ensure that, notwithstanding such holders’ aggregate voting power exceeds 70%, their voting power will be capped at 70%. Open the document at this passage
Oct 8
Current report 6-K
Current report

Quantum BioPharma Ltd. announced that the United States District Court for the Southern District of New York consolidated its direct action and an investor-led class action alleging market manipulation, appointing Grant & Eisenhofer P.A. as lead counsel.

Oct 6
Current report 6-K
Current report

Quantum BioPharma entered a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to implement the randomized, double-blind, placebo-controlled Phase 2 Lucid-MS trial in progressive multiple sclerosis.

Sep 24
Current report 6-K
Current report

Quantum BioPharma said licensee Unbuzzd Wellness Inc. appointed Michael “Zappy” Zapolin as CEO to pursue financing, a stock-exchange listing and a U.S. rollout. Quantum retains 19.48% of Unbuzzd, with a 7% royalty until $250 million, then 3% in perpetuity.

2025
Showing 1–50 of 319 documents
Key facts CIK 1771885 CUSIP 74764Y205 13F (30d) 28 filings 26 filers Visit website Investor relations